All questions are shown as received by the Trust.
Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment
Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
a. Atezolizumab (Tecentriq)
b. Avelumab (Bavencio)
c. Carboplatin single agent or in any other combination
d. Carboplatin with Gemcitabine
e. Carboplatin with Paclitaxel
f. Cisplatin single agent or in any other combination
g. Cisplatin with Gemcitabine
h. Cisplatin with Gemcitabine + Nivolumab (Opdivo)
i. Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
j. Nivolumab (Opdivo)
k. Pembrolizumab (Keytruda)
l. Other active systemic anti-cancer therapy
m. Palliative care only
Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy

Urothelial cancer and non-small cell lung cancer (NSCLC).160824.docx